The Fourth Annual Meeting of the European Vascular Genomics Network (EVGN, www.evgn.org), Network of excellence on cardiovascular disease, opened yesterday, September 17th, in the prestigious venue of the University of Bristol (UK), that made available to the event two historical buildings: the Wills Memorial Building, inaugurated by King George V and Queen Mary, and the Merchant Venturers Building.
Run jointly with the European Vascular Biology Organization (EVBO) and the British Atherosclerosis Society and articulated over a three day period (September 17-20), the EVGN Meeting will take place in parallel with the 4th European Meeting on Vascular Biology and Medicine (EMVBM), gathering more than 400 scientists from all over Europe with representatives from the rest of the world. Cardiologists and diabetes researchers, as well as hematologists, thrombosis scientists, gene therapists and oncologists will alternate their presentations to show new data and debate perspectives on the therapeutic side.
“Once again as we did in 2005 – said the President of EVBO Professor Andrew Newby – the simultaneous presence of renowned scientists with different expertise and competence is a unique chance to confront news and views on controversial aspects of vascular disease, an elusive but deadly disease, and to enhance the productivity and the competitiveness of the European scientific community at large”.
The agenda is more than full: 10 plenary speakers, a selection of 45 oral presentations and almost 200 posters complete a rich and comprehensive programme. And tomorrow, Sept. 19, the Young Investigator Award will be assigned to a young distinguished researcher, with the aim of encouraging his/her investigations in years to come.
The opening Hugh Sinclair lecture that concluded the first day of the Meeting was presented by Professor Goran K. Hansson, from the Karolinska Hospital, Center for Molecular Medicine, who offered an elegant state-of-the-art summary of atherosclerosis, with an eye to the most appealing therapeutic perspective: a vaccine against this immune disease. “The current knowledge of atherosclerosis has markedly changed over the latest years” said Hansson, who is a leading scientists in the immunology field. “Today we know that atherosclerosis is an inflammatory disease with both a systemic association and a genetic involvement. Inside the plaques there is a strong immune activity, and day after day we learn more and more about the immunopathogenetic mechanisms with the aid of mouse models that mimic the disease in humans. But we are still a few steps away from a human trial”. There are three unresolved issues. We need: to find the proper antigen for immunization (a good candidate is the LDL particle, Low Density Lipoprotein or bad cholesterol); to clarify the mechanism of action (it has to be decided whether the vaccine wants to reduce bad circulating lipoproteins or act upon immune cells that create inflammation in the artery); finally, we have to identify the optimal administration route. “When we overcome these bottlenecks, we will get to the vaccine.”
Today, September 18th, the EVGN scientists will address some of the most critical topics for cardiovascular disease:
• strategies to modulate angiogenesis (the growth of blood vessels which is necessary to avoid tissue necrosis after ischemia);
• ways to target atherosclerotic plaques;
• the clinical experience in the acute myocardial infarction
“Most of the convened scientists – commented Professor Newby – are at the fore front of the research. We expect interesting news from this fourth EVGN Meeting. We also want to start proceeding on new therapeutic avenues, to improve scientists’ interactions and encourage young talents”.
The European Vascular Genomics Network (EVGN) is the first Network of Excellence on cardiovascular disease funded by the European Commission under the 6th Framework Programme "Life sciences, genomics and biotechnology for health" (Contract Number: LSHM-CT-2003-503254).
The conference is supported by an unrestricted educational grant from Laboratoires SERVIER.
Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg
New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences